GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Willow Biosciences Inc (OTCPK:CANSF) » Definitions » ROE % Adjusted to Book Value

CANSF (Willow Biosciences) ROE % Adjusted to Book Value : -96.92% (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Willow Biosciences ROE % Adjusted to Book Value?

Willow Biosciences's ROE % for the quarter that ended in Sep. 2024 was -7,076.92%. Willow Biosciences's PB Ratio for the quarter that ended in Sep. 2024 was 73.02. Willow Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -96.92%.


Willow Biosciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Willow Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Willow Biosciences ROE % Adjusted to Book Value Chart

Willow Biosciences Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -176.48 - -22.55 -73.68 -39.91

Willow Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -64.61 -63.66 -44.66 - -96.92

Competitive Comparison of Willow Biosciences's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Willow Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Willow Biosciences's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Willow Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Willow Biosciences's ROE % Adjusted to Book Value falls into.


;
;

Willow Biosciences ROE % Adjusted to Book Value Calculation

Willow Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-132.91% / 3.33
=-39.91%

Willow Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-7,076.92% / 73.02
=-96.92%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Willow Biosciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Willow Biosciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Willow Biosciences Business Description

Traded in Other Exchanges
Address
202, 1201 5th Street SW, Calgary, AB, CAN, T2R 0Y6
Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. It has a geographic presence in Canada and the United states, in which it generates the majority of its revenue from the United states.